TUXEDO-2 Trial: Supraflex Cruz Stent Shows Comparable Outcomes to Xience in Diabetic Patients
The TUXEDO-2 trial compared the Supraflex Cruz stent with the Xience stent in diabetic patients with multivessel coronary artery disease. Results showed comparable procedural success and safety outcomes between the two stents, supporting the non-inferiority of Supraflex Cruz.
The TUXEDO-2 trial, led by Dr. Upendra Kaul, is a landmark study comparing the Supraflex Cruz biodegradable polymer sirolimus-eluting stent with the Xience durable polymer everolimus-eluting stent in diabetic patients with multivessel coronary artery disease. The trial enrolled 1,800 patients across 66 Indian centers, with 85% having triple-vessel disease. Preliminary findings indicated high procedural success and comparable safety profiles between the two stents. The study aimed to establish the non-inferiority of Supraflex Cruz, highlighting its potential in managing complex diabetic coronary disease.
